Evidence map›Paper›PMID 29317342›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2018

Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model.

Qilai Long, Tzu-Yin Lin, Yee Huang, Xiaocen Li, Ai-Hong Ma, Hongyong Zhang, Randy Carney, Susan Airhart, Kit S Lam, Ralph W deVere White and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Engineering the Surface of TiPharmaceutics · 2022
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Fidelity of a PDX-CR model for bladder cancer.Biochemical and biophysical research communications · 2019
    Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Qilai LongDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Internal Medicine, University of California Davis, Sacramento, CA, USA.
Tzu-Yin LinDepartment of Internal Medicine, University of California Davis, Sacramento, CA, USA.
Yee HuangDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA, USA; Institute of Animal Husbandry and Veterinary Science, Zhejiang Academy of Agricultural Sciences.
Xiaocen LiDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA, USA.
Ai-Hong MaDepartment of Internal Medicine, University of California Davis, Sacramento, CA, USA.
Hongyong ZhangDepartment of Internal Medicine, University of California Davis, Sacramento, CA, USA.
Randy CarneyDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA, USA.
Susan AirhartThe Jackson Laboratory, Bar Harbor, Maine, USA.
Kit S LamDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA, USA.
Ralph W deVere WhiteDepartment of Urology, University of California Davis, Sacramento, CA, USA.
Chong-Xian PanDepartment of Internal Medicine, University of California Davis, Sacramento, CA, USA; Department of Urology, University of California Davis, Sacramento, CA, USA; VA Northern California Health Care System, Mather, CA. Electronic address: cxpan@ucdavis.edu.
Yuanpei LiDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA, USA. Electronic address: lypli@ucdavis.edu.
University of California, Davis · USJackson Laboratory · USZheJiang Academy of Agricultural Sciences · CN

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development ProgramK12CA138464 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BIRKELAND, ANDREW CHARLES, LARA, PRIMO N. · 2011 to 2025
$11.4M
Targeted-and timed-releasing nanotherapeutics against leukemia stem cellsR01CA176803 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PAN, CHONG-XIAN · 2015 to 2019
$1.8M
Stimuli-responsive crosslinked theranostics against advanced prostate cancerR01CA199668 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2015 to 2019
$1.8M
Smart targeting nano-theranostics for image-guided drug delivery to pediatric brain tumorsR01HD086195 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2016 to 2020
$1.6M
Development of targeting nanotherapeutics against bladder cancerI01BX001784 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI PAN, CHONG-XIAN · 2014 to 2017
–
BLRD VA I01 BX001784BLRD VA I01 BX003840NCI NIH HHS K12 CA138464NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA176803NCI NIH HHS R01 CA199668NICHD NIH HHS R01 HD086195
6 · The paper itself

Abstract

Photodynamic therapy is a promising and effective non-invasive therapeutic approach for the treatment of bladder cancers. Therapies targeting HSP90 have the advantage of tumor cell selectivity and have shown great preclinical efficacy. In this study, we evaluated a novel multifunctional nanoporphyrin platform loaded with an HSP90 inhibitor 17AAG (NP-AAG) for use as a multi-modality therapy against bladder cancer. NP-AAG was efficiently accumulated and retained at bladder cancer patient-derived xenograft (PDX) over 7 days. PDX tumors could be synergistically eradicated with a single intravenous injection of NP-AAG followed by multiple light treatments within 7 days. NP-AAG mediated treatment could not only specifically deliver 17AAG and produce heat and reactive oxygen species, but also more effectively inhibit essential bladder cancer essential signaling molecules like Akt, Src, and Erk, as well as HIF-1α induced by photo-therapy. This multifunctional nanoplatform has high clinical relevance and could dramatically improve management for bladder cancers with minimal toxicity.

Indexed as

PhotochemotherapyAged, 80 and overAnimalsBenzoquinonesCell SurvivalCombined Modality TherapyFemaleHSP90 Heat-Shock ProteinsHumansLactams, MacrocyclicMiceMice, Inbred NODMice, SCIDMolecular ImagingMolecular Targeted TherapyNanoparticlesBenzoquinonesHSP90 Heat-Shock ProteinsLactams, MacrocyclicPorphyrinsReactive Oxygen SpeciestanespimycinBladder cancerHSP90 inhibitorNanoparticlePhotodynamic therapyPhotothermal therapy

Identifiers

PMID29317342
PMCPMC5898975
OpenAlexW2781985986

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.